Out Of The Pipeline
Out Of The Pipeline
Triple-bead mixed amphetamine salt for ADHD
Stimulants are first-line psychopharmacologic interventions for attention-deficit/hyperactivity disorder (ADHD), and their efficacy is supported...
Out Of The Pipeline
Valbenazine for tardive dyskinesia
Despite improvements in the tolerability of antipsychotic medications, the development of tardive dyskinesia (TD) still is a significant area of...
Out Of The Pipeline
Pimavanserin for psychosis in patients with Parkinson’s disease
Pimavanserin is a potent 5-HT2A inverse agonist and 5-HT2C inverse agonist, with 5-fold greater affinity for the 5-HT2A receptor.1...
Out Of The Pipeline
Long-acting injectable aripiprazole lauroxil for schizophrenia
Out Of The Pipeline
Extended-release, orally disintegrating mixed amphetamine salts for ADHD: New formulation
Patients taking the capsule form of extended-release mixed amphetamine salts can be switched to this new orally disintegrating formulation, which...
Out Of The Pipeline
Flibanserin for hypoactive sexual desire disorder in premenopausal women
Out Of The Pipeline
Cariprazine for schizophrenia and bipolar I disorder
As a dopamine D3-preferring D3/D2 partial agonist, cariprazine offers an alternative to antipsychotics that preferentially modulate D2 receptors...
Out Of The Pipeline
Cariprazine for schizophrenia and bipolar I disorder
As a dopamine D3-preferring D3/D2 partial agonist, cariprazine offers an alternative to antipsychotics that preferentially modulate D2 receptors...
Out Of The Pipeline
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder
Brexpiprazole, FDA-approved in July 2015 to treat schizophrenia and as an adjunct for major depressive disorder (MDD), has shown efficacy in 2...